{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:20:03Z","timestamp":1793049603307,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sanaria Inc."},{"name":"University of Washington Primate Research Center","award":["P51OD010425 (WaNPRC)"],"award-info":[{"award-number":["P51OD010425 (WaNPRC)"]}]},{"name":"University of Washington Primate Research Center","award":["P51OD010425 (WaNPRC)"],"award-info":[{"award-number":["P51OD010425 (WaNPRC)"]}]},{"name":"Intramural Research Program, NIAID"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      (Pf) sporozoite (SPZ) vaccines are the only candidate malaria vaccines that induce\u2009&gt;\u200990% vaccine efficacy (VE) against controlled human malaria infection and the only malaria vaccines to have achieved reproducible VE against malaria in adults in Africa. The goal is to increase the impact and reduce the cost of PfSPZ vaccines by optimizing vaccine potency and manufacturing, which will benefit from identification of immunological responses contributing to protection in humans. Currently, there is no authentic animal challenge model for assessing\n                      <jats:italic>P. falciparum<\/jats:italic>\n                      malaria VE. Alternatively,\n                      <jats:italic>Plasmodium knowlesi<\/jats:italic>\n                      (Pk), which infects humans and non-human primates (NHPs) in nature, can be used to experimentally infect rhesus macaques (\n                      <jats:italic>Macaca mulatta<\/jats:italic>\n                      ) to assess VE.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sanaria has, therefore, produced purified, vialed, cryopreserved PkSPZ and conducted challenge studies in several na\u00efve NHP cohorts. In the first cohort, groups of three rhesus macaques each received doses of 5\u2009\u00d7\u200910\n                      <jats:sup>2<\/jats:sup>\n                      , 2.5\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      , 1.25\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      and 2.5\u2009\u00d7\u200910\n                      <jats:sup>4<\/jats:sup>\n                      PkSPZ administered by direct venous inoculation. The infectivity of 1.5\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      \u00a0PkSPZ cryopreserved with an altered method and of 1.5\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      \u00a0PkSPZ cryopreserved for\u00a0four years was tested in a second and third cohort of rhesus\u00a0NHPs. The lastly, three pig-tailed macaques (\n                      <jats:italic>Macaca nemestrina<\/jats:italic>\n                      ), a natural\n                      <jats:italic>P. knowlesi<\/jats:italic>\n                      host, were challenged with 2.5\u2009\u00d7\u200910\n                      <jats:sup>3<\/jats:sup>\n                      PkSPZ\u00a0cryopreserved six years earlier.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the first cohort, all 12 animals developed\n                      <jats:italic>P. knowlesi<\/jats:italic>\n                      parasitaemia\u00a0by thick blood smear, and the time to positivity (prepatent period) followed a non-linear 4-parameter logistic sigmoidal model with a median of 11, 10, 8, and 7 days, respectively (r\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20091). PkSPZ cryopreserved using a modified rapid-scalable method infected rhesus with a pre-patent period of 10 days, as did PkSPZ cryopreserved four years prior to infection, similar to the control group. Cryopreserved PkSPZ infected pig-tailed macaques with median time to positivity by thin smear, of 11 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study establishes the capacity to consistently infect NHPs with purified, vialed, cryopreserved PkSPZ, providing a foundation for future studies to probe protective immunological mechanisms elicited by PfSPZ vaccines that cannot be established in humans.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-022-04261-z","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T03:02:39Z","timestamp":1661569359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites"],"prefix":"10.1186","volume":"21","author":[{"given":"Sumana","family":"Chakravarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Shears","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvashi","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solomon","family":"Conteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn E.","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick E.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,27]]},"reference":[{"key":"4261_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, et al. Live attenuated malaria vaccine designed to protect through hepatic CD8 + T cell immunity. Science. 2011;334:475\u201380.","journal-title":"Science"},{"key":"4261_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2012.12-0613","volume":"88","author":"M Roestenberg","year":"2013","unstructured":"Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2013;88:5\u201313.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR3","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science. 2013;341:1359\u201365.","journal-title":"Science"},{"key":"4261_CR4","doi-asserted-by":"publisher","first-page":"e65960","DOI":"10.1371\/journal.pone.0065960","volume":"8","author":"SH Sheehy","year":"2013","unstructured":"Sheehy SH, Spencer AJ, Douglas AD, Sim BK, Longley RJ, Edwards NJ, et al. Optimising controlled human malaria infection studies using cryopreserved parasites administered by needle and syringe. PLoS ONE. 2013;8:e65960.","journal-title":"PLoS ONE"},{"key":"4261_CR5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4269\/ajtmh.14-0119","volume":"91","author":"S Shekalaghe","year":"2014","unstructured":"Shekalaghe S, Rutaihwa M, Billingsley PF, Chemba M, Daubenberger CA, James ER, et al. Controlled human malaria infection of tanzanians by intradermal injection of aseptic, purified, cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg. 2014;91:471\u201380.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR6","doi-asserted-by":"publisher","first-page":"686","DOI":"10.3389\/fmicb.2014.00686","volume":"5","author":"SH Hodgson","year":"2014","unstructured":"Hodgson SH, Juma EA, Salim A, Magiri C, Kimani D, Njenga D, et al. Evaluating controlled human malaria infection in kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection. Front Microbiol. 2014;5:686.","journal-title":"Front Microbiol"},{"key":"4261_CR7","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.15-0621","author":"GJ Bastiaens","year":"2015","unstructured":"Bastiaens GJ, Van Meer MP, Scholzen A, Obiero JM, Vatanshenassan M, Van Grinsven T, et al. Safety, immunogenicity, and protective efficacy of intradermal immunization with aseptic, purified, cryopreserved Plasmodium falciparum sporozoites in volunteers under chloroquine prophylaxis: a randomized controlled trial. Am J Trop Med Hyg. 2015. https:\/\/doi.org\/10.4269\/ajtmh.15-0621.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12936-015-0817-x","volume":"14","author":"GP Gomez-Perez","year":"2015","unstructured":"Gomez-Perez GP, Legarda A, Munoz J, Sim BK, Ballester MR, Dobano C, et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar J. 2015;14:306.","journal-title":"Malar J"},{"key":"4261_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.4269\/ajtmh.15-0341","volume":"93","author":"KE Lyke","year":"2015","unstructured":"Lyke KE, Laurens MB, Strauss K, Adams M, Billingsley PF, James E, et al. Optimizing intradermal administration of cryopreserved Plasmodium falciparum sporozoites in controlled human malaria infection. Am J Trop Med Hyg. 2015;93:1274\u201384.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller B, Supan C, Sim KL, G\u00f3mez-P\u00e9rez GP, Ospina Salazar CL, Held J, et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar J. 2015;14:117.","journal-title":"Malar J"},{"key":"4261_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka AS, Lyke KE, Dezure A, Berry AA, Richie TL, Mendoza FH, et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat Med. 2016;22:614\u201323.","journal-title":"Nat Med"},{"key":"4261_CR12","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein JE, Paolino KM, Richie TL, Sedegah M, Singer A, Ruben AJ, et al. Protection against Plasmodium falciparum malaria by PfSPZ vaccine. JCI Insight. 2017;2:e89154.","journal-title":"JCI Insight"},{"key":"4261_CR13","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordmuller","year":"2017","unstructured":"Mordmuller B, Surat G, Lagler H, Chakravarty S, Ishizuka AS, Lalremruata A, et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature. 2017;542:445\u20139.","journal-title":"Nature"},{"key":"4261_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko MS, Healy SA, Katile A, Omaswa F, Zaidi I, Gabriel EE, et al. Safety and efficacy of pfspz vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis. 2017;17:498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"4261_CR15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, Dezure A, Enama ME, et al. Attenuated pfspz vaccine induces strain-transcending t cells and durable protection against heterologous controlled human malaria infection. Proc Natl Acad Sci U S A. 2017;114:2711\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4261_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu A, Urbano V, Hamad A, Eka M, Chemba M, Nyakarungu E, et al. Advancing global health through development and clinical trials partnerships: a randomized, placebo-controlled, double-blind assessment of safety, tolerability, and immunogenicity of Plasmodium falciparum sporozoites vaccine for malaria in healthy Equatoguinean men. Am J Trop Med Hyg. 2018;98:308\u201318.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","volume":"98","author":"B Lell","year":"2018","unstructured":"Lell B, Mordmuller B, Dejon Agobe JC, Honkpehedji J, Zinsou J, Mengue JB, et al. Impact of sickle cell trait and naturally acquired immunity on uncomplicated malaria after controlled human malaria infection in adults in Gabon. Am J Trop Med Hyg. 2018;98:508\u201315.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo SA, Shekalage SA, Church LWP, Ruben AJ, Schindler T, Zenklusen I, et al. Safety, immunogenicity, and protective efficacy against controlled human malaria infection of Plasmodium falciparum sporozoite vaccine in Tanzanian adults. Am J Trop Med Hyg. 2018;99:338\u201349.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR19","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo SA, Church LWP, Mtoro AT, Chakravarty S, Ruben AJ, Swanson PA, et al. Safety and differential antibody and t-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019;100:1433\u201344.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR20","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/330664a0","volume":"330","author":"L Schofield","year":"1987","unstructured":"Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig RS, Nussenzweig V. Gamma-interferon, CD8 + T cells and antibodies required for immunity to malaria sporozoites. Nature. 1987;330:664\u20136.","journal-title":"Nature"},{"key":"4261_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1073\/pnas.85.2.573","volume":"85","author":"WR Weiss","year":"1988","unstructured":"Weiss WR, Sedegah M, Beaudoin RL, Miller LH, Good MF. Cd8 + t cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci U S A. 1988;85:573\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4261_CR22","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1084\/jem.171.3.763","volume":"171","author":"WR Weiss","year":"1990","unstructured":"Weiss WR, Mellouk S, Houghten RA, Sedegah M, Kumar S, Good MF, et al. Cytotoxic t cells recognize a peptide from the circumsporozoite protein on malaria-infected hepatocytes. J Exp Med. 1990;171:763\u201373.","journal-title":"J Exp Med"},{"key":"4261_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","volume":"165","author":"DL Doolan","year":"2000","unstructured":"Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J Immunol. 2000;165:1453\u201362.","journal-title":"J Immunol"},{"key":"4261_CR24","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1128\/IAI.69.9.5565-5572.2001","volume":"69","author":"WO Rogers","year":"2001","unstructured":"Rogers WO, Baird JK, Kumar A, Tine JA, Weiss W, Aguiar JC, et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in Rhesus macaques. Infect Immun. 2001;69:5565\u201372.","journal-title":"Infect Immun"},{"key":"4261_CR25","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.1128\/IAI.70.8.4329-4335.2002","volume":"70","author":"WO Rogers","year":"2002","unstructured":"Rogers WO, Weiss WR, Kumar A, Aguiar JC, Tine JA, Gwadz R, et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect Immun. 2002;70:4329\u201335.","journal-title":"Infect Immun"},{"key":"4261_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20170869","volume":"215","author":"SW Scally","year":"2018","unstructured":"Scally SW, Murugan R, Bosch A, Triller G, Costa G, Mordmuller B, et al. Rare pfcsp c-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection. J Exp Med. 2018;215:63\u201375.","journal-title":"J Exp Med"},{"key":"4261_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.apar.2021.08.005","volume":"113","author":"I Vythilingam","year":"2021","unstructured":"Vythilingam I, Chua TH, Liew JWK, Manin BO, Ferguson HM. The vectors of Plasmodium knowlesi and other simian malarias southeast asia: challenges in malaria elimination. Adv Parasitol. 2021;113:131\u201389.","journal-title":"Adv Parasitol"},{"key":"4261_CR28","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/bs.apar.2021.08.006","volume":"113","author":"PR Cuenca","year":"2021","unstructured":"Cuenca PR, Key S, Jumail A, Surendra H, Ferguson HM, Drakeley CJ, et al. Epidemiology of the zoonotic malaria Plasmodium knowlesi in changing landscapes. Adv Parasitol. 2021;113:225\u201386.","journal-title":"Adv Parasitol"},{"key":"4261_CR29","doi-asserted-by":"publisher","first-page":"e0008900","DOI":"10.1371\/journal.pntd.0008900","volume":"14","author":"NK Jeyaprakasam","year":"2020","unstructured":"Jeyaprakasam NK, Liew JWK, Low VL, Wan-Sulaiman WY, Vythilingam I. Plasmodium knowlesi infecting humans in southeast asia: what\u2019s next? PLoS Negl Trop Dis. 2020;14:e0008900.","journal-title":"PLoS Negl Trop Dis"},{"key":"4261_CR30","doi-asserted-by":"publisher","first-page":"e0171826","DOI":"10.1371\/journal.pone.0171826","volume":"12","author":"S Pichyangkul","year":"2017","unstructured":"Pichyangkul S, Spring MD, Yongvanitchit K, Kum-Arb U, Limsalakpetch A, Im-Erbsin R, et al. Chemoprophylaxis with sporozoite immunization in P. Knowlesi rhesus monkeys confers protection and elicits sporozoite-specific memory t cells in the liver. PLoS ONE. 2017;12:e0171826.","journal-title":"PLoS ONE"},{"key":"4261_CR31","doi-asserted-by":"publisher","first-page":"e31247","DOI":"10.1371\/journal.pone.0031247","volume":"7","author":"WR Weiss","year":"2012","unstructured":"Weiss WR, Jiang CG. Protective CD8 + T lymphocytes in primates immunized with malaria sporozoites. PLoS ONE. 2012;7:e31247.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"4261_CR32","first-page":"165","volume":"57","author":"RW Gwadz","year":"1979","unstructured":"Gwadz RW, Cochrane AH, Nussenzweig V, Nussenzweig RS. Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowlesi and characterization of surface antigens of these parasites. Bull World Health Organ. 1979;57(Suppl 1):165\u201373.","journal-title":"Bull World Health Organ"},{"key":"4261_CR33","doi-asserted-by":"publisher","first-page":"e100138","DOI":"10.1371\/journal.pone.0100138","volume":"9","author":"CV Hobbs","year":"2014","unstructured":"Hobbs CV, Neal J, Conteh S, Donnelly L, Chen J, Marsh K, et al. Hiv treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivo. PLoS ONE. 2014;9:e100138.","journal-title":"PLoS ONE"},{"key":"4261_CR34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman SL, Billingsley P, James E, Richman A, Loyevsky M, Li T, et al. Development of a metabolically active,non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccines. 2010;6:97\u2013106.","journal-title":"Hum Vaccines"},{"key":"4261_CR35","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.1128\/JCM.02549-12","volume":"50","author":"SC Murphy","year":"2012","unstructured":"Murphy SC, Daza G, Chang M, Coombs R. Laser cutting eliminates nucleic acid cross-contamination in dried-blood-spot processing. J Clin Microbiol. 2012;50:4128\u201330.","journal-title":"J Clin Microbiol"},{"key":"4261_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/jcp.49.7.533","volume":"49","author":"DC Warhurst","year":"1996","unstructured":"Warhurst DC, Williams JE. Acp broadsheet no 148. July 1996. Laboratory diagnosis of malaria. J Clin Pathol. 1996;49:533\u20138.","journal-title":"J Clin Pathol"},{"key":"4261_CR37","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1073\/pnas.79.18.5651","volume":"79","author":"AH Cochrane","year":"1982","unstructured":"Cochrane AH, Santoro F, Nussenzweig V, Gwadz RW, Nussenzweig RS. Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A. 1982;79:5651\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4261_CR38","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2307\/3284159","volume":"82","author":"JS Sullivan","year":"1996","unstructured":"Sullivan JS, Morris CL, Richardson BB, Galland GG, Sullivan JJ, Collins WE. Sporozoite transmission of three strains of Plasmodium knowlesi to aotus and Saimiri monkeys. J Parasitol. 1996;82:268\u201371.","journal-title":"J Parasitol"},{"key":"4261_CR39","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1645\/GE-3348RN","volume":"90","author":"WE Collins","year":"2004","unstructured":"Collins WE, Sullivan JS, Nace D, Williams T, Williams A, Galland GG, et al. Additional observations on the sporozoite transmission of Plasmodium knowlesi to monkeys. J Parasitol. 2004;90:866\u20137.","journal-title":"J Parasitol"},{"key":"4261_CR40","doi-asserted-by":"publisher","first-page":"841","DOI":"10.2307\/3276783","volume":"53","author":"WE Collins","year":"1967","unstructured":"Collins WE, Contacos PG, Guinn EG. Studies on the transmission of simian malarias. Ii. Transmission of the h strain of Plasmodium knowlesi by Anopheles balabacensis balabacensis. J Parasitol. 1967;53:841\u20134.","journal-title":"J Parasitol"},{"key":"4261_CR41","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/cid\/ciy1087","volume":"69","author":"JC Dejon-Agobe","year":"2019","unstructured":"Dejon-Agobe JC, Ateba-Ngoa U, Lalremruata A, Homoet A, Engelhorn J, Paterne Nouatin O, et al. Controlled human malaria infection of healthy lifelong malaria-exposed adults to assess safety, immunogenicity and efficacy of the asexual blood stage malaria vaccine candidate GMZ2. Clin Infect Dis. 2019;69:1377\u201384.","journal-title":"Clin Infect Dis"},{"key":"4261_CR42","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","volume":"220","author":"MB Laurens","year":"2019","unstructured":"Laurens MB, Berry AA, Travassos MA, Strauss K, Adams M, Shrestha B, et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J Infect Dis. 2019;220:1962\u20136.","journal-title":"J Infect Dis"},{"key":"4261_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12936-015-0671-x","volume":"14","author":"SH Hodgson","year":"2015","unstructured":"Hodgson SH, Juma E, Salim A, Magiri C, Njenga D, Molyneux S, et al. Lessons learnt from the first controlled human malaria infection study conducted in nairobi, kenya. Malar J. 2015;14:182.","journal-title":"Malar J"},{"key":"4261_CR44","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie TL, Billingsley PF, Sim BK, Epstein JE, Lyke KE, Mordmuller B, et al. Progress with plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine. 2015;33:7452\u201361.","journal-title":"Vaccine"},{"key":"4261_CR45","doi-asserted-by":"publisher","first-page":"499","DOI":"10.4269\/ajtmh.2004.70.499","volume":"70","author":"DS Walsh","year":"2004","unstructured":"Walsh DS, Pichyangkul S, Gettayacamin M, Tongtawe P, Siegrist CA, Hansukjariya P, et al. Safety and immunogenicity of RTS,S + Trap malaria vaccine, formulated in the AS02A adjuvant system, in infant rhesus monkeys. Am J Trop Med Hyg. 2004;70:499\u2013509.","journal-title":"Am J Trop Med Hyg"},{"key":"4261_CR46","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.vaccine.2010.10.041","volume":"29","author":"S Capone","year":"2010","unstructured":"Capone S, Reyes-Sandoval A, Naddeo M, Siani L, Ammendola V, Rollier CS, et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector adch63 and mva prime-boost immunisation in non-human primates. Vaccine. 2010;29:256\u201365.","journal-title":"Vaccine"},{"key":"4261_CR47","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/aid.2006.22.580","volume":"22","author":"CJ Batten","year":"2006","unstructured":"Batten CJ, De Rose R, Wilson KM, Agy MB, Chea S, Stratov I, et al. Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses. 2006;22:580\u20138.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4261_CR48","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1586\/14760584.7.9.1419","volume":"7","author":"S Baroncelli","year":"2008","unstructured":"Baroncelli S, Negri DR, Michelini Z, Cara A. Macaca mulatta, fascicularis and nemestrina in aids vaccine development. Expert Rev Vaccines. 2008;7:1419\u201334.","journal-title":"Expert Rev Vaccines"},{"key":"4261_CR49","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1600-0684.2011.00488.x","volume":"40","author":"T Henning","year":"2011","unstructured":"Henning T, Fakile Y, Phillips C, Sweeney E, Mitchell J, Patton D, et al. Development of a pigtail macaque model of sexually transmitted infection\/hiv coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and shiv(sf162p3). J Med Primatol. 2011;40:214\u201323.","journal-title":"J Med Primatol"},{"key":"4261_CR50","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41467-018-05826-w","volume":"9","author":"MA O\u2019connor","year":"2018","unstructured":"O\u2019connor MA, Tisoncik-Go J, Lewis TB, Miller CJ, Bratt D, Moats CR, et al. Early cellular innate immune responses drive zika viral persistence and tissue tropism in pigtail macaques. Nat Commun. 2018;9:3371.","journal-title":"Nat Commun"},{"key":"4261_CR51","first-page":"43","volume":"86","author":"AL Cole","year":"2018","unstructured":"Cole AL, Cosgrove Sweeney Y, Lasseter AG, Gray JM, Beavis AC, Chong CF, et al. Evaluation of the pig-tailed macaque (Macaca nemestrina) as a model of human Staphylococcus aureus nasal carriage. Infect Immun. 2018;86:43.","journal-title":"Infect Immun."},{"key":"4261_CR52","doi-asserted-by":"publisher","first-page":"e157-e8","DOI":"10.1016\/S2542-5196(19)30061-0","volume":"3","author":"DM Parker","year":"2019","unstructured":"Parker DM. Humans, macaques, and malaria parasites in a shared and changing landscape. Lancet Planet Health. 2019;3:e157\u20138.","journal-title":"Lancet Planet Health"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04261-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04261-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04261-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T08:06:50Z","timestamp":1661587610000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04261-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,27]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4261"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04261-z","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,27]]},"assertion":[{"value":"18 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"S.C., E.R.J., U.R., N.K.C., and S.L.H. are employees of Sanaria Inc, and draw their salaries from the company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"247"}}